openPR Logo
Press release

Opioids Market to Surpass US$ 25.7 Billion by 2024

10-11-2017 04:45 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Opioid drugs act on the opioid receptors present in the central and peripheral nervous system. The drug class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids. Codeine, morphine, hydrocodone, oxycodone, heroin, and fentanyl are some of the major prescription drugs in the global opioids market. Opioids can be administered as oral pills, parenteral, liquids, patches, or lozenges. Overdose and drug abuse is a major concern for health regulators worldwide, with the situation especially alarming in developed regions with easy access to these drugs. According to the World Drug Report 2016, a staggering 17.4 million people were affected by opioid drug abuse. Drug and health regulators are therefore, taking initiatives to govern pain prescriptions and curb the rate of opioid abuse. The U.S. FDA considers all opioids as schedule 2 drugs—drugs that have high abuse potential. In 2016, the CDC issued guidelines to prescribe opioids, limiting the daily dose of opioids to 90 morphine milligram equivalent (MME).

Request a sample copy of this report: http://bit.ly/2yZW1cP

According to the National Institutes of Health (NIH) estimates published in 2015 by the American Pain Society, nearly 50 million people in the U.S. suffered from chronic pain. Use of opioids in cancer pain, orthopedic pain, neuropathic pain, post-operative pain, and lower back pain is very effective. With growing incidence of chronic pain, demand for opioids will also increase consequently.

North America is the largest market for opioids owing to availability of branded prescription and local products, which inadvertently also leads to drug abuse. There are local unbranded products available for every opioid derivative complementing the available prescription opioid brand. The Centers for Disease Control and Prevention (CDC) states that 73% of all drug overdose deaths in the U.S. in 2015 were due to opioids (57% in 2010). Moreover, emergence of cannabis as an alternative to opioids and legalization of the same in various regions is inhibiting the opioids market growth.

Opioids market majorly impacted by rising adoption of cannabis

The global opioids market experiences volatility due to various factors such as rampant production of opium and inclination of the masses towards use of alternate drugs such as cannabis. Cannabis is now being legalized in most parts of the U.S.—the major consumer of cannabis drug. Moreover, cannabis is the most cultivated drug crop in the world. Also, consumers in the U.S. find administering cannabis more effective than opioids, which is also impacting consumption of opioids. Due to this, Colorado is experiencing a decline in the number of opioid deaths. Cannabis is considered to be a healthy alternative to opioids. U.S. accounted for 77% share in the global opioids market in 2015. A study conducted by researchers at the University of British Columbia, found that 32% of Canadians switched from using opioids to cannabis for relieving pain. Production of opium according to the World Drug Report 2016 declined in 2015 by 38% compared to that in 2014.

Click here to know more about this publish report: http://bit.ly/2g2A3hS

Increasing drug abuse impacting the opioids market outlook

The U.S. FDA considers all opioids as schedule 2 drugs—drugs that have high abuse potential. Codeine, fentanyl, meperidine, methadone, morphine, and hydrocodone are the most abused prescription opioid analgesics. Contrary to other regions, wherein codeine is expected to dominate the market globally, North America is expected to be primarily driven by sales of hydrocodone opioids. Drug abuse with opioid is characterized by prolonged use or overdosing of the prescribed medication. A 2015 study by the CDC concluded that people who are addicted to prescription analgesics are 40 times more likely to be addicted to heroin. Furthermore, CDC also states that 73% of all drug overdose deaths in the U.S. in 2015 were due to opioids (57% in 2010). Although the use of prescription opioid for non-medical purpose has decreased over 2012–2014, use of heroin has increased significantly during this period. The deaths accounted due to opioid abuse has also increased consequently over the years. According to the National Institutes of Health (NIH) 2015 data, there was a 2.8 fold increase in deaths in the U.S. due to overdose of opioid during 2002–2014. The death incidence rose to nearly 33,000 in 2015 from 23,000 in 2012 in the U.S. Similarly, non-prescription use of cough syrups containing codeine is also a major issue to be addressed.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Opioids Market to Surpass US$ 25.7 Billion by 2024 here

News-ID: 768625 • Views:

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic foot ulcers treatment market
Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017 – 2025
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2025 globally
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug